Ansun Biopharma
Stephen Hawley has over 25 years of experience in the biopharmaceutical industry. Stephen started their career in 1994 as a Postdoctoral Researcher at The Scripps Research Institute, where they discovered, purified, identified, cloned, expressed and characterized multiple novel receptors responsible for monocytoid cell surface-dependent plasminogen activation. Theirfindings were published in peer-reviewed journals with high impact factor. In 2000, they joined Arizeke as a Senior Scientist. In 2004, they moved to NexBio Inc., where they held the role of Director, Process Development & Manufacturing, Associate Director, Process Development and Assistant Director, Process Development. In 2008, they were promoted to Senior Director, Drug Substance Development and Director, Drug Substance Development. In 2015, they joined Ansun Biopharma, Inc. as a Senior Principal Scientist.
Stephen Hawley completed a Ph.D. in Cellular Biochemistry from UC Irvine.
Ansun Biopharma
Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics.